老年人肝脏纤维化的诊疗进展

doi:10.3969/j.issn.1003-9198.2026.07.004

摘要/Abstract

摘要： 衰老与肝脏纤维化之间存在复杂的双向调控关系。老年肝脏纤维化患者在病因构成、病理生理特征、合并疾病谱及治疗耐受性等方面具有特异性,本文围绕老年肝脏纤维化的常见病因与临床特点、衰老与肝脏纤维化相关机制、肝脏纤维化诊断进展及抗纤维化治疗策略进行系统综述,指出未来还需优化非侵入性诊断手段,并制定个体化、综合性的抗纤维化治疗策略。

关键词: 老年人, 肝脏纤维化, 衰老

Abstract: A complex bidirectional regulatory relationship exists between aging and liver fibrosis. Elderly patients with liver fibrosis demonstrate distinct features in etiology, pathophysiology, comorbidity patterns, and treatment tolerance. This paper systematicly reviews current knowledge on the common causes and clinical characteristics of geriatric liver fibrosis, the mechanisms underlying the aging-fibrosis interplay, progress in diagnostic modalities, and emerging anti-fibrotic therapies. The review highlights the urgent need to refine non-invasive diagnostic approaches and to develop individualized, multifaceted anti-fibrotic management strategies tailored to the elderly population.

Key words: aged, liver fibrosis, aging

中图分类号:

R 575.2

王思亚, 殷实. 老年人肝脏纤维化的诊疗进展[J]. 实用老年医学, 2026, 40(7): 662-666.

WANG Siya, YIN Shi. Advances in the diagnosis and management of liver fibrosis in the elderly[J]. Practical Geriatrics, 2026, 40(7): 662-666.

参考文献

[1] United Nations Department of Economic and Social Affairs, Population Division. World population prospects 2024: summary of results[R]. New York: United Nations, 2024.
[2] CHANG A Y, SKIRBEKK V F, TYROVOLAS S, et al. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017[J]. Lancet Public Health, 2019, 4(3): e159-e167.
[3] WIJAYASIRI P, ASTBURY S, KAYE P, et al. Role of hepatocyte senescence in the activation of hepatic stellate cells and liver fibrosis progression[J]. Cells, 2022, 11(14): 2221.
[4] YANG Z, LI A, JIANG Y, et al. Global burden of metabolic dysfunction-associated steatotic liver disease attributable to high fasting plasma glucose in 204 countries and territories from 1990 to 2021[J]. Sci Rep, 2024, 14: 22232.
[5] SINCLAIR S 3rd, SHEAREN S, GHOBRIAL Y, et al. Review of the effects of antiviral therapy on hepatitis B/C-related mortality and the regression of fibrosis[J]. Viruses, 2024, 16(10): 1531.
[6] NIU X, ZHU L, XU Y, et al. Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis[J]. BMC Public Health, 2023, 23(1): 859.
[7] COHEN E B, PATWARDHAN M, RAHEJA R, et al. Drug-induced liver injury in the elderly: consensus statements and recommendations from the IQ-DILI initiative[J]. Drug Saf, 2024, 47(4): 301-319.
[8] SHABBIR M, SALAZAR M, KAYALI Z. Impact of age on mortality and decompensation events in patients with liver cirrhosis: a multicenter, propensity score matched study[J]. Int J Hepatol, 2025, 2025: 8852224.
[9] BADAWI R, FAHMY ABOU TAIRA N S, HASBY S E, et al. The association of liver fibrosis and chronic kidney disease in patients with metabolic associated fatty liver disease: a cross-sectional study[J]. Saudi Med J, 2024, 45(10): 1034-1040.
[10] TONG C, XUE Y, WANG W, et al. Advanced liver fibrosis, but not MASLD, is associated with accelerated biological aging: a population-based study[J]. BMC Public Health, 2024, 24(1): 3293.
[11] SAGAR P, PERUMAL S K, RAJAMANICKAM R, et al. Aging promotes spontaneous liver injury: insights from metabolic, inflammatory, and fibrotic pathways in C57BL/6 mice[J]. Biomolecules, 2025, 15(12): 1727.
[12] DAI Q, QING X, JIANG W, et al. Aging aggravates liver fibrosis through downregulated hepatocyte SIRT1-induced liver sinusoidal endothelial cell dysfunction[J]. Hepatol Commun, 2023, 8(1): e0350.
[13] PENG X, LI P, ZHANG Y, et al. Aging increases susceptibility to liver fibrosis through enhanced NAT10-mediated ac4C modification of TGFβ1 mRNA[J]. Genome Med, 2025, 17(1): 90.
[14] HUANG Y, HE W, ZHANG Y, et al. Targeting SIRT2 in aging-associated fibrosis pathophysiology[J]. Aging Dis, 2024, 16(4): 2036-2053.
[15] BANG M, FAN W, WONG N D. Liver fibrosis according to diabetes status and relation to cardiovascular risk and mortality in US adults[J]. Am Heart J Plus, 2024, 46: 100457.
[16] THOMAIDES-BREARS H B, ALKHOURI N, ALLENDE D, et al. Incidence of complications from percutaneous biopsy in chronic liver disease: a systematic review and meta-analysis[J]. Dig Dis Sci, 2022, 67(7): 3366-3394.
[17] JOHANNES H, MALTE W, SHAIMA A, et al. Right and left liver lobe biopsies by minilaparoscopy reveal clinically significant sampling error in staging and grading of autoimmune hepatitis[J]. Liver Int, 2023, 43(6): 1269-1276.
[18] 黄素钦, 林城, 郑思彧. 血清CHI3L1、GP73和肝纤四项联合检测对慢性乙型肝炎早期肝纤维化的诊断价值[J]. 肝脏, 2025, 30(9): 1219-1224.
[19] HUANG C, SEAH J J, TAN C K, et al. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101528.
[20] HARRISON S A, OLIVER D, ARNOLD H L, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease[J]. Gut, 2008, 57(10): 1441-1447.
[21] KIMURA S, TAMAKI N, HIGUCHI M, et al. Diagnostic accuracy of FIB-4 index and FIB-3 index for advanced fibrosis in chronic liver disease and age-specific thresholds[J]. J Clin Med, 2025, 14(23): 8473.
[22] 王蒙蒙, 朱宇清, 杨曦明, 等. 肝纤维化非创伤性实验诊断专家共识[J]. 检验医学, 2025, 40(7): 625-641.
[23] LUO Q T, ZHU Q, ZONG X D, et al. Diagnostic performance of transient elastography versus two-dimensional shear wave elastography for liver fibrosis in chronic viral hepatitis: direct comparison and a meta-analysis[J]. Biomed Res Int, 2022, 2022: 1960244.
[24] BI J, LIU L, QIN T. Comparison of magnetic resonance elastography and transient elastography in the diagnosis of hepatic fibrosis: a systematic review and meta-analysis[J]. Ann Palliat Med, 2021, 10(8): 8692-8700.
[25] 雷其良, 董志辉, 高鹏, 等. 多排螺旋CT灌注成像对肝炎、肝纤维化及早期肝硬化诊断的临床价值[J]. 社区医学杂志, 2018, 16(11): 69-70.
[26] NAIDU K B B, BELLUR V C, OUDIT O, et al. Diagnostic accuracy of artificial intelligence in the diagnosis of liver fibrosis: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2025, 120(S10): S544.
[27] KASHYAP K, FARGOSE S, DABRE C, et al. Hybrid approach combining ultrasound and blood test analysis with a voting classifier for accurate liver fibrosis and cirrhosis assessment[PP/OL]. arXiv. (2025-04-28)[2026-03-16]. https://arxiv.org/abs/2504.19755.
[28] 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[29] VIDAL-CEVALLOS P, SORROZA-MARTÍNEZ A P, CHÁVEZ-TAPIA N C, et al. The relationship between pathogenesis and possible treatments for the MASLD-cirrhosisspectrum[J]. Int J Mol Sci, 2024, 25(8): 4397.
[30] KONG L Z, CHANDIMALI N, HAN Y H, et al. Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease[J]. Int J Mol Sci, 2019, 20(11): 2712.
[31] NOZAKI A, CHUMA M, HARA K, et al. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: a prospective observational study[J]. Medicine: Baltimore, 2021, 100(12): e25110.
[32] HSU W H, LEE B H, HSU Y W, et al. Peroxisome proliferator-activated receptor-γ activators monascin and rosiglitazone attenuate carboxymethyllysine-induced fibrosis in hepatic stellate cells through regulating the oxidative stress pathway but independent of the receptor for advanced glycation end products signaling[J]. J Agric Food Chem, 2013, 61(28): 6873-6879.
[33] NAN Y M, FU N, WU W J, et al. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice[J]. Scand J Gastroenterol, 2009, 44(3): 358-365.
[34] SALAH M M, ASHOUR A A, ABDELGHANY T M, et al. Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice[J]. Life Sci, 2019, 239: 116982.
[35] OGAWA S, OCHI T, SHIMADA H, et al. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development[J]. Hepatol Res, 2010, 40(11): 1128-1141.
[36] SANYAL A J, LOPEZ P, LAWITZ E J, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial[J]. Nat Med, 2023, 29(2): 392-400.
[37] ZHANG K, ZHANG M X, MENG X X, et al. Targeting GPR65 alleviates hepatic inflammation and fibrosis by suppressing the JNK and NF-κB pathways[J]. Mil Med Res, 2023, 10(1): 56.
[38] KIM G, KIM J, LIM Y L, et al. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review[J]. Hepatol Int, 2016, 10(5): 819-828.